In today's health care industry, the competition for the most respected, experienced physicians is heating up. This is true not only for health care delivery organizations, it is also a challenge for pharmaceutical companies seeking key opinion leaders (KOLs) to help them in researching, launching, and marketing new drugs. KOLs offer valuable insights into disease states and patient treatment regimens, in addition to new product exposure through medical literature and their professional circles.
Pharma companies that excel at building relationships with key opinion leading physicians open doors that enable them to disseminate new product information and clinical trial results to the medical community through trusted sources.
This article features results from research by Cutting Edge Information, a pharmaceutical business intelligence firm in Durham, North Carolina. Cutting Edge studied winning practices in thought leader management and has worked closely with more than a dozen KOL management executives from industry leaders, such as Pfizer, AstraZeneca and GlaxoSmithKline.